Oppenheimer Asset Management Inc. Biomarin Pharmaceutical Inc Transaction History

Oppenheimer Asset Management Inc.

$8.04 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$74.43 - $92.22 $2,009 - $2,489	27 Added 0.61%	4,473 $368,000
Q1 2024 May 06, 2024	SELL	$83.81 - $99.0 $9,135 - $10,791	-109 Reduced 2.39%	4,446 $388,000
Q4 2023 Feb 13, 2024	SELL	$76.22 - $98.51 $24,314 - $31,424	-319 Reduced 6.54%	4,555 $439,000
Q3 2023 Nov 07, 2023	BUY	$85.07 - $94.48 $130,582 - $145,026	1,535 Added 45.97%	4,874 $431,000
Q2 2023 Aug 02, 2023	SELL	$86.68 - $100.3 $24,270 - $28,084	-280 Reduced 7.74%	3,339 $289,000
Q1 2023 May 10, 2023	SELL	$87.74 - $117.27 $210,137 - $280,861	-2,395 Reduced 39.82%	3,619 $351,000
Q4 2022 Feb 06, 2023	SELL	$80.93 - $108.63 $2,670 - $3,584	-33 Reduced 0.55%	6,014 $622,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $153,885 - $181,568	1,873 Added 44.87%	6,047 $513,000
Q2 2022 Aug 08, 2022	SELL	$71.48 - $86.85 $10,364 - $12,593	-145 Reduced 3.36%	4,174 $346,000
Q1 2022 May 12, 2022	SELL	$74.28 - $92.69 $523,896 - $653,742	-7,053 Reduced 62.02%	4,319 $333,000
Q4 2021 Feb 02, 2022	BUY	$71.72 - $91.47 $9,251 - $11,799	129 Added 1.15%	11,372 $1.01 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $455,124 - $520,255	-6,087 Reduced 35.12%	11,243 $869,000
Q2 2021 Aug 03, 2021	BUY	$75.51 - $84.79 $44,928 - $50,450	595 Added 3.56%	17,330 $1.45 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $790,195 - $958,956	-10,574 Reduced 38.72%	16,735 $1.26 Million
Q4 2020 Feb 11, 2021	BUY	$72.61 - $90.2 $99,112 - $123,123	1,365 Added 5.26%	27,309 $2.4 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $104,427 - $190,386	1,453 Added 5.93%	25,944 $1.97 Million
Q2 2020 Aug 11, 2020	BUY	$79.55 - $124.22 $72,310 - $112,915	909 Added 3.85%	24,491 $3.02 Million
Q1 2020 May 08, 2020	BUY	$71.37 - $96.85 $276,059 - $374,615	3,868 Added 19.62%	23,582 $1.99 Million
Q4 2019 Feb 07, 2020	SELL	$64.27 - $86.37 $75,388 - $101,312	-1,173 Reduced 5.62%	19,714 $1.67 Million
Q3 2019 Oct 31, 2019	BUY	$67.4 - $85.11 $124,690 - $157,453	1,850 Added 9.72%	20,887 $1.41 Million
Q2 2019 Aug 09, 2019	SELL	$80.35 - $93.9 $8,758 - $10,235	-109 Reduced 0.57%	19,037 $1.63 Million
Q1 2019 Apr 24, 2019	SELL	$84.2 - $98.62 $940,598 - $1.1 Million	-11,171 Reduced 36.85%	19,146 $1.7 Million
Q4 2018 Jan 30, 2019	BUY	$80.14 - $106.07 $80 - $106	1 Added 0.0%	30,317 $2.58 Million
Q3 2018 Oct 26, 2018	BUY	$93.92 - $105.72 $66,025 - $74,321	703 Added 2.37%	30,316 $2.94 Million
Q2 2018 Aug 10, 2018	BUY	$76.01 - $99.03 $284,809 - $371,065	3,747 Added 14.49%	29,613 $2.79 Million
Q1 2018 May 09, 2018	BUY	$77.67 - $92.63 $73,631 - $87,813	948 Added 3.8%	25,866 $2.1 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $2.01 Million - $2.37 Million	24,918	24,918 $2.32 Million

Others Institutions Holding BMRN

# of Institutions

635

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.44 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.22 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.2 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$881 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$666 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Account